CivicaScript, a unit of hospital-owned nonprofit drug company Civica Rx, has launched its first low-cost generic drug available in the outpatient pharmacy setting: abiraterone acetate (brand name Zytiga) used to treat metastatic prostate cancer. The company will sell abiraterone to
…
Drug manufacturer Boehringer Ingelheim (BI) said on Friday that health centers will be subject to its limits on 340B pricing involving contract pharmacies starting Sept. 1. The restrictions previously applied to hospitals only. “At this time, for all other federal
…
Patients receiving inpatient care at 340B disproportionate share hospitals are significantly more likely to be low income than those receiving outpatient care, according to a new study funded by the brand name drug trade group PhRMA.
Hospital eligibility in the
…
Purdue Pharma’s Avrio Health subsidiary is giving 340B covered entities refunds for overcharges on Betasept antiseptic surgical scrub for purchases spanning 16 years—from Q2 2005 through Q2 2021. That period covers more than half of the 340B program’s existence.
During
…
The brand drug industry’s recent full-page ad in The Washington Post saying the 340B program helps big hospitals and chain pharmacies but not patients is “hypocritical slander,” AIDS Healthcare Foundation President Michael Weinstein said last week.
“PhRMA calling for drug price
…
A Special Report From 340B Report:
A two-part series on the growing frustrations safety net providers face in restoring access to 340B pricing in the contract pharmacy setting. Part 1 provides important background on the challenges that covered entities face and
Pharmaceutical Research and Manufacturers of America ran a full-page advertisement in the A section of The Washington Post this morning blasting 340B hospitals and drug store chains. According to a PhRMA spokesperson, it is part of a new ad campaign
…
California will start making its own insulin under a state budget bill Gov. Gavin Newsom (D) signed June 30.
The bill includes $50 million to develop three low-cost biosimilar insulin products and another $50 million for a California-based insulin-manufacturing facility.
…
For the fourth time this year, drug manufacturer Lilly has announced refunds for overcharges on 340B-purchased drugs during 2019.
The U.S. Health Resources and Services Administration (HRSA) posted the notice, dated May 27, on the Office of Pharmacy Affairs website
…
×
*Sign up for news summaries and alerts from 340B Report